FOXO4-p53 interfering peptide
FOXO4-DRI is a senolytic peptide derived from the forkhead box O transcription factor 4, designed to selectively induce apoptosis in senescent cells. Researchers primarily study it for its potential role in targeting cellular senescence, a process linked to aging and various diseases. Key findings indicate that FOXO4-DRI disrupts the interaction between FOXO4 and the p53 protein, promoting the nuclear exclusion of phosphorylated p53 and enhancing apoptosis in senescent endothelial cells and fibroblasts. Additionally, studies suggest that FOXO4-DRI may improve vascular function and mitigate the effects of aging-related senescence in various cell types. Current research is focused on elucidating its mechanisms of action and exploring its therapeutic applications in age-related conditions and proliferative disorders.
| Formula | C228H388N86O64 |
| Molecular Weight | 5358 g/mol |
| CAS Number | 2460055-10-9 |
| PubChem CID | 167312269 |
Not applicable
Poor bioavailability
Pharmacokinetic properties are still under investigation, with a focus on optimizing delivery methods.
FOXO4-DRI selectively induces apoptosis in senescent cells by disrupting the interaction between FOXO4 and the p53 transactivation domain, promoting the nuclear exclusion of phosphorylated p53 (p53-pS15). This mechanism activates the p53/BCL-2/Caspase-3 signaling pathway, leading to apoptosis and alleviating cellular senescence. While the precise molecular interactions are characterized, further investigation is needed to fully elucidate all aspects of this mechanism.
508
Total Citations
3
Human/RCT
2.7
Avg. Influence
2025
Latest
The study demonstrated that FOXO4-DRI induces forced apoptosis of senescent cells in the kidney, leading to improved kidney function during aging in animal models.
Born Emmanuelle, et al. · Circulation · 2023
Researchers observed that the elimination of senescent pulmonary endothelial cells by senolytic interventions may worsen pulmonary hemodynamics in mouse models of pulmonary arterial hypertension.
Key findings
Meng Jingshu, et al. · JCI insight · 2021
The study demonstrated that FOXO4-DRI induces apoptosis in senescence-like cancer-associated fibroblasts, enhancing radiosensitivity in non-small cell lung cancer and alleviating radiation-induced pulmonary fibrosis in vivo.
Key findings
Huang Yuzhao, et al. · Frontiers in bioengineering and biotechnology · 2021
Researchers observed that FOXO4-DRI effectively removed senescent cells from in vitro expanded human chondrocytes, reducing senescence levels but not enhancing their chondrogenic potential.
Key findings
Han Xiaodan, et al. · Journal of cellular and molecular medicine · 2022
Researchers observed that FOXO4-DRI decreases senescent cells and attenuates morphological changes in bleomycin-induced pulmonary fibrosis in mice, suggesting its potential as a therapeutic option.
Key findings
Researchers observed that FOXO4-DRI disrupts the FOXO4-p53 interaction, restoring p53's apoptotic function and improving tissue homeostasis in senescent cells.
Bourgeois Benjamin, et al. · Nature communications · 2025
The study demonstrated that FOXO4-DRI selectively binds to the disordered p53 transactivation domain, enhancing the potential for developing p53 inhibitors targeting cellular senescence.
Key findings
Kong Yu-Xiang, et al. · Communications biology · 2025
The study demonstrated that FOXO4-DRI induces apoptosis in keloid senescent fibroblasts by promoting nuclear exclusion of phosphorylated p53, suggesting its potential in targeting senescence-related aggressiveness.
Key findings
Liu Ying, et al. · Naunyn-Schmiedeberg's archives of pharmacology · 2023
The study demonstrated that FOXO4-DRI ameliorates bleomycin-induced pulmonary fibrosis in mice by reducing collagen deposition and promoting nuclear exclusion of p53.
Key findings
The study demonstrated that FOXO4-DRI is a promising anti-aging peptide, contributing to the development of anti-aging drugs based on molecular mechanisms of aging.
No randomized controlled human trials have been conducted to evaluate the efficacy and safety of FOXO4-DRI in diverse patient populations. Additionally, the long-term effects of FOXO4-DRI treatment on cellular senescence and overall health outcomes remain unclear, particularly in relation to potential adverse effects or the risk of tumorigenesis.
Solubility
FOXO4-DRI is soluble in water and DMSO, with limited solubility in organic solvents like acetonitrile.
Lyophilized
Stable for 2+ years at -20°C, 12 months at 4°C
Reconstituted
Use within 14 days when refrigerated at 4°C
Avoid
Avoid repeated freeze-thaw cycles, direct light
Solvent
Bacteriostatic water or sterile saline recommended
Safety information is derived from published research and may not reflect all known risks. This is not medical advice.
🇩🇪DE
Not approved as a medicinal product. Not a controlled substance. Sale as research chemical is a legal grey area.
🇺🇸US
Not approved by the FDA. Not scheduled by the DEA.
🇦🇺AU
Not listed in the TGA schedules.
🇬🇧UK
Not approved by the MHRA for medicinal use.
Legal status information is provided for general reference only and may not reflect the most current regulatory changes. Always verify with official government sources before making any decisions.
Publications per Year
12 total| Vendor | Amount | Price | Price/mg | Link |
|---|---|---|---|---|
BESTRCpeptidesEU | 10mg | $54.00 | $5.40/mg | |
PeptiLab USAUS | 10mg | $77.99 | $7.80/mg | |
XL PeptidesUK | 10mg | $88.89 | $8.89/mg | |
Ruo BioUS | 10mg | $100.00 | $10.00/mg | |
Ion PeptideUS | 10mg | $119.00 | $11.90/mg |
Top 5 of 21 offers from 21 vendors. Prices updated daily.
See all FOXO4-DRI pricesLog your research cycles, set reminders and visualize serum levels.
This page is for informational and research purposes only. All information is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Many substances listed may not be approved for human use and may be subject to drug regulation laws (e.g., AMG in Germany, FDA in the US). PepStack does not encourage the use of any substance on humans. Always consult a qualified healthcare professional before making any health-related decisions. Use of this information is entirely at your own risk. PepStack assumes no liability for the accuracy, completeness, or timeliness of the content provided. Full disclaimer